Introduction
Dravet syndrome (also known as severe myoclonic epilepsy of infancy) is an intractable childhood epileptic encephalopathy with onset in the first year of life. The incidence of Dravet syndrome was initially estimated at 1 in 30,000-40,000 live births [2, 3] , although data from a California-based population identified an incidence of 1 per 15,000-20,000 [4] . In most cases, Dravet syndrome is caused by de novo mutations of the SCN1A gene that encodes for the alphasubunit of the neuronal voltage-gated sodium channel [5] . SCN1A gene mutations are found in 70-90% of patients with a clinical diagnosis of Dravet syndrome [4, 6] .
Children with Dravet syndrome are healthy and have normal development prior to seizure onset [7] . Seizures often start within the first year of life and are characterized by frequent and prolonged febrile seizures that are often hemiclonic. Multiple seizure types can occur over time, including atypical absence, myoclonic, generalized tonic clonic, and focal onset seizures. EEG findings are initially normal but with time background slowing and focal or generalized and polyspike wave discharges appear, which may persist into adulthood [8] .
Other features of Dravet syndrome have been described including neurocognitive decline and ataxia [7, 9] . Behavioral disturbances with hyperactivity and autistic features are often present during early childhood [10] . Studies into adulthood have identified motor abnormalities and impaired walking, as well as cerebellar features such as ataxia, dysarthria, intention tremor, and eye movement disorders [8] . Prior descriptions of children with Dravet syndrome and their phenotype are available in the literature and have not reported endocrine or growth abnormalities.
Little is known of the exact relationship between endocrine abnormalities and epilepsy, especially in children. In adult literature, endocrine abnormalities have been reported in 20-25% of women with temporal lobe epilepsy prior to treatment with anti-seizure medication [11] . A small case control study of children with both focal onset and idiopathic generalized epilepsy treated with carbamazepine or valproate monotherapy found epilepsy patients to have reduced linear growth as compared to controls, but with normal IGF-1 testing [12] . Other studies of children with epilepsy have reported normal linear growth [13, 14] . There is more known about the effect of anti-seizure medications on endocrine function. Anti-seizure medications themselves (valproate, phenobarbital, carbamazepine) can be associated with endocrine dysfunction, including short stature, increased testosterone levels, and thyroid dysfunction [15, 16] . Furthermore, there is concern that the ketogenic diet can also lead to poor growth long-term but again the evidence is inconsistent.
In the literature, there is no report of growth abnormalities or endocrine dysfunction in children with Dravet syndrome, although clinically we have noted short stature and weight concerns, as well as abnormal endocrine labs in several of our patients with Dravet syndrome. The aim of the current study is to evaluate growth parameters and characterize endocrine abnormalities in children with Dravet syndrome.
Methods
A retrospective chart review was performed at Children's Hospital of Colorado from September 1999 until May 2015. Children were identified from a clinical database of Dravet syndrome patients and also by interrogation of the electronic medical record for the diagnosis of Dravet syndrome or SCN1A gene mutation. Eligibility criteria included both a clinical diagnosis of Dravet syndrome and positive SCN1A genetic testing. SCN1A variants of unknown significance were included if there was a clinical presentation consistent with Dravet syndrome. Parental report of positive SCN1A genetic testing was allowed if prior records were not available. Patients with a clinical diagnosis of Dravet syndrome without confirmatory genetic testing were excluded. Study data were collected and managed using REDCap electronic data capture tools hosted at University of Colorado Denver [17] . REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. Records were reviewed for height and weight measurements and serologic evidence of endocrine abnormality, including growth hormone, sex hormones, cortisol, and thyroid testing, as well as for demographic information, current anti-epileptic medication, and family history of endocrine disease.
All available growth measurements (height and weight) for the entire study cohort of 68 patients were downloaded from our electronic medical record (EPIC). The growth parameters of children between the ages of 2 and 19 were included in the height and weight analyses and compared to CDC 2000 growth curves [1, 18] . Growth measurements taken at an age of less than two years old were excluded as caloric intake and nutritional status, as well as social factors, are key determinants of growth at this age, and less likely underlying genetic potential. By the time children are 18-24 months old they tend to be closer to their genetically predetermined percentile [19] . Single individuals may have had multiple height and weight measurements captured over time. Differences in the same week were considered measurement error, so measures taken in the same week were averaged. Height and weight measurements that changed by more than 5% and 10%, respectively, or were determined to be biologically implausible values (BIV), were examined and removed if deemed to be data entry errors (n = 7). All measurements after initiation of hormonal treatment (testosterone or growth hormone) were excluded from the analysis.
Age and gender-specific height and weight z-scores are calculated from the CDC 2000 growth charts [1] . A z-score represents the difference from the CDC reference population and is expressed in standard deviations from the mean. Multiple measures on a single subject were considered in the analysis. In order to analyze the trend of height and weight (in z-scores) of children with Dravet syndrome as age increases, a linear mixed regression model with a random intercept and slope (age) with an unstructured covariance structure was used. The linearity of age was examined by plotting cubic splines, as well as various loess curves [20] . The Akaike's Information Criteria (AIC) was used to determine model fit. All analyses were performed using Statistical Analysis Systems (SAS Institute, Cary, NC, ver. 9.4) Serologic endocrine results were available for only a subset of patients in the study cohort. Screening endocrine testing was often ordered by the child neurologist due to growth concerns with referral to an endocrinologist if testing was abnormal. Not all children with poor growth had endocrine testing available. Endocrine results outside of the age based normal range, as defined by the testing laboratory, were considered abnormal. These results are presented in frequencies and percent using descriptive statistics.
Results
There were 68 records that met eligibility criteria. The cohort consisted of 46% males, with a median age of 9 years (range 1-21), currently taking an average of 2.9 anti-seizure medications per Of the 68 children included in the study, the growth measurements for four children were excluded based on the child's age less than two years-old. Growth measurements were available for the remaining 64 children from September 1999 to May 2015. The number of weight measurements on a single child ranged from 1 to 128 with a maximum follow-up time of 14.6 years (Interquartile range: 1-7.9 years). For height, the number of measurements on a single child ranged from 1 to 59 with a maximum follow-up time of 13.4 years (Interquartile range: 0.9-7.5 years).
Growth measurements are notable for a significant decrease in the mean height and weight z-score with age. For every year increase in age there was a decrease in height z-score of 0.10 (p = < 0.001) and a decrease in weight z-score of 0.09 (p = < 0.01). Therefore, with increasing age, both the height and weight z-score of children with Dravet syndrome become more disparate with the normal growth curve. The average height and weight z-score for this cohort, at age 8, was À0.45 and À0.09, respectively. Percentiles are calculated by transforming predicted mean z-scores from a linear mixed regression model. Mean predicted height and weight percentiles over time are shown in Figs. 1 and 2 , respectively, based on the CDC height and weight norms. Individual measurements are also presented as points on the graph. The 50th percentile based on CDC growth charts is shown as a solid horizontal line. After adjusting for age neither gender, family history, or anti-seizure medications was associated with height or weight z-score. The data from the linear mixed regression model is available as a supplementary table.
Endocrine testing was performed in 26 (38%, N = 68) of the total children (Table 2 ) with notable abnormalities in 7 (47%, n = 15) children tested for insulin-like growth factor 1 (IGF-1), a common screening surrogate for growth hormone status. Testosterone levels were low in 2 (20%, n = 10) of children tested and, to a lesser extent, this is also a screening surrogate for growth hormone status. Two children with low IGF-1 levels had further growth hormone stimulation testing that confirmed growth hormone deficiency. Additionally, two children with low IGF-1 levels had low testosterone levels. One child had pan-hypopituitarism with low IGF-1, TSH, and cortisol that self-resolved and was no longer requiring treatment. Two children received treatment with testosterone for delayed puberty, one of whom also received treatment with growth hormone for short stature. Two additional children with low IGF-1 levels had poor weight gain and one additional child with low IGF-1 was on the ketogenic diet. When checked, TSH levels were frequently normal. Other sex hormone values (LH, FSH, estradiol) were available in some records but were difficult to interpret due to the absence of pubertal information, and as a result are not reported. Cortisol levels were checked in eight patients and low in only one patient, but this result is not reliable, as it was in the late morning and checked due to hypotension during an intensive care unit admission that improved without steroid treatment.
Discussion
Children with Dravet syndrome in a single institution cohort demonstrate reduced height and weight growth trend with shorter stature and lower weight compared to gender and age specific population based norms (p = < 0.001 and p = < 0.01, respectively). There was also abnormal endocrine testing in a subset of patients, most commonly low IGF-1 and testosterone levels. Serologic testing for thyroid abnormalities was often normal. There was not enough information available regarding pubertal development to reliably interpret the results of sex hormone testing. Similarly, cortisol levels were checked at variable times of day and also cannot be reliably interpreted.
In this retrospective cohort of children with Dravet syndrome, there was no clear predictor of alteration in height or weight other than age. Short stature is defined by individual height that is two standard deviations (SDs) or more below the average height for age, sex, and ethnic group or more than two SDs below midparental height. There is a broad differential to consider with the diagnosis of short stature that includes variants of normal growth (familial short stature, constitutional delay of growth and puberty, small for gestational age with failure of catch-up growth, and early Fig. 1 . Predicted mean height percentile by age of children with Dravet syndrome. puberty) but also pathologic etiologies including genetic disorders (Prader-Willi, Turner Syndrome, Noonan Syndrome), chronic systemic disease, long-term steroid use, nutritional deficiencies, malignancies, and primary endocrine abnormalities [19, [21] [22] [23] [24] . Growth hormone deficiency is estimated to affect 1/3500 children [22, 24] . Low IGF-1 levels and confirmed growth hormone deficiency occurred in two patients in this cohort of children with Dravet syndrome, which is much higher than the incidence in the general population. Of children with short stature, 60-80% will not have a cause identified and be given the diagnosis of idiopathic short stature. The change in height identified in these children with Dravet syndrome is not thought to be due to familial short stature since typically SCN1A mutations are de novo, therefore, parents do not carry the same mutation as their child, and in a large cohort of individuals, parent height would be assumed to fall within population based norms. Mid-parental height would have been helpful to more completely assess for familial short stature in this population, but was unable to be completed due to the retrospective nature of this study and lack of this data in charts.
This population of patients with Dravet syndrome also demonstrated reduced weight percentiles with increasing age. Failure to thrive or weight faltering is most commonly defined as weight for age that falls below the 5th percentile on multiple occasions or weight deceleration that crosses two major percentile lines on a growth chart [25] . This is relatively common and seen in 5-10% of children in the primary care setting with the most common etiology of inadequate caloric intake [25] . Reduced weight gain or weight loss that precedes slowing of linear growth is consistent with inadequate caloric intake as the etiology for poor growth. In our population of patients with Dravet syndrome, height failure started at a younger age than weight failure and this pattern goes against insufficient caloric intake as an etiology for reduced growth. Nutritional malabsorption or increased metabolic demand, such as congenital heart disease, celiac disease, chronic diarrhea, chronic pulmonary disease, hyperthyroidism, among others, are all additional etiologies to consider when failure to thrive is not caused by inadequate caloric intake include [25] . These other reasons for failure to thrive are not typically seen in children with Dravet syndrome and are not expected to be present in our cohort of patients. However, charts were not reviewed for these alternative diagnoses, except for evidence of thyroid disease, and other possible etiologies could be further evaluated in future studies.
The number of anti-seizure medications did not have an effect on height or weight in this study. Children with Dravet syndrome are often on several medications concurrently due to the refractory nature of their epilepsy. Some anti-seizure medications cause anorexia (topiramate and zonisamide, as key examples) and others cause an increased appetite and weight gain (i.e., valproic acid). It is commonly suggested that the ketogenic diet could be associated with growth concerns, although in a study by Coppola, et. al., only one patient out of 38 treated with the ketogenic diet, demonstrated weight loss while on the diet [26] . A systemic literature review of adverse effects with ketogenic diet also did not identify weight loss as an adverse effect [27] . In our study, 8 (12%) patients were on the ketogenic diet at the time of data collection and 22 (32%) children had been on the ketogenic diet in the past. Descriptive data were notable for one child with low IGF-1 but normal stature that was on the ketogenic diet. In this child the low IGF-1 level could be related to the ketogenic diet, according to prospective data reporting a decrease in IGF-1 levels after initiation of the ketogenic diet [28] . However, this prior study did not include repeat IGF-1 levels or evaluate growth after diet discontinuation. Given the lack of literature to support that long-term growth failure occurs secondary to the ketogenic diet, it should not be assumed that the ketogenic diet is responsible for the growth changes in this cohort of children with Dravet syndrome. However, it may be that the anorexic and orexigenic effects of the various anti-seizure treatments counter-balanced each other such that there was no net effect on weight. For example, 51% (n = 35) of patients were currently taking valproic acid and 24% (n = 16) taking topiramate, although it is not known how many patients received both medications concurrently. Medication combinations and length of exposure to each medication, including ketogenic diet, could not be evaluated in this study as several of the patients transferred care into the study site with limited prior records regarding earlier treatment course. This could be better evaluated in future prospective studies. Testosterone levels were checked in ten patients, and two were identified as lower than expected. In adolescent males, testosterone levels may be used to evaluate for delayed puberty or hypogonadism. LH and FSH levels can be used to distinguish between testicular failure and decreased pituitary signaling due to either delayed puberty or hypogonadotropic hypogonadism, but these values were not reliably able to be interpreted in our study. The two patients with low testosterone levels received a short course of testosterone supplementation as treatment for delayed puberty by their endocrinologist. Delayed puberty can be a familial trait or be due to other factors that affect growth including underweight, chronic illness, or hypopituitarism [29] . We did not have detailed puberty information on all patients to be able to further characterize their sex hormone status.
A primary limitation of this study is the retrospective study design that reduces the ability to control for confounding variables, such as the timing and length of treatment for each anti-seizure medication. Additionally, the growth parameters themselves are subject to measurement error and for each patient there is a different baseline age and variable number of follow-up measurements. There are also fewer growth measurements for children at older ages and this may influence the true cohort mean and calculated z-score with increasing age. The decrease in measurements with age is likely because of the young age of the cohort and loss of patients that no longer follow-up in our neurology clinic. As mentioned above, mid-parental height was not available for comparison, and this would be helpful in further evaluating the changes in stature, as parental height helps predict expected height for a child. Height velocity is another approach to evaluating growth but could not be used due to compounding error with calculations of repeat measures that are already associated with substantial variability and moderate sample size. Additionally, this cohort of children with Dravet syndrome was compared to the general population by CDC growth curves. It is difficult to know if the growth changes reported are due to the SCN1A gene mutation itself or related to the subsequent epileptic encephalopathy that develops. Future studies should consider comparison to another population of children with epileptic encephalopathy (such as Doose syndrome or Lennox-Gastaut syndrome). The results could also vary depending on the type of SCN1A gene mutation (i.e. frameshift vs missense) and this information was not consistently available for all individuals in the current study. In addition to adding a comparison group, following patients prospectively would provide a more accurate depiction of growth over time in children with Dravet syndrome and help address the above limitations.
Overall, our data suggests that children with Dravet syndrome may indeed have short stature and have some evidence of endocrine dysfunction. Additional studies are needed in this area to further characterize these changes. At this time, it would be reasonable to consider endocrine evaluation for children with Dravet syndrome that have evidence of growth delay or short stature until further research can better characterize and evaluate the etiology of these changes.
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Appendix A
See Table A1 . a Least Squared means from the mixed linear regression model are z-score = intercept + age + characteristic with a random intercept and age. b Tests whether the B in the model is different from 0. For Average mean Z-score at 8 years old it tests whether the least squared mean is different from zero.
